


Doxepin-d₃ hydrochloride

| | | | | | | | | | | | | | |
|---------------------------|--|----------|-------|---------|--|-----|---------|------------|-------|----------|--|-------|---------|
| Cat. No.: | HY-B0725S | | | | | | | | | | | | |
| CAS No.: | 347840-07-7 | | | | | | | | | | | | |
| Molecular Formula: | C ₁₉ H ₁₉ D ₃ ClNO | | | | | | | | | | | | |
| Molecular Weight: | 318.86 | | | | | | | | | | | | |
| Target: | Histamine Receptor; Cytochrome P450 | | | | | | | | | | | | |
| Pathway: | GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Metabolic Enzyme/Protease | | | | | | | | | | | | |
| Storage: | <table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table> | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
| Powder | -20°C | 3 years | | | | | | | | | | | |
| | 4°C | 2 years | | | | | | | | | | | |
| In solvent | -80°C | 6 months | | | | | | | | | | | |
| | -20°C | 1 month | | | | | | | | | | | |



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (313.62 mM)
 H₂O : ≥ 50 mg/mL (156.81 mM)
 * "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent Concentration | Mass | | |
|---------------------------|-----------------------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| | 1 mM | 3.1362 mL | 15.6809 mL | 31.3617 mL |
| | 5 mM | 0.6272 mL | 3.1362 mL | 6.2723 mL |
| | 10 mM | 0.3136 mL | 1.5681 mL | 3.1362 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Doxepin-d₃ (hydrochloride) is a deuterium labeled Doxepin Hydrochloride. Doxepin hydrochloride is an orally active tricyclic antidepressant. Doxepin hydrochloride is a potent and selective histamine receptor H₁ antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2[1][2].

IC₅₀ & Target

Histamine receptor H₁; CYP450 2C19 and CYP450 1A2[2]

REFERENCES

[1]. Hajak, G., et al., Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry, 2001. 62(6): p. 453-63.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA